These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25759125)

  • 21. Reactivation of Epstein-Barr virus in B cells of patients with chronic hepatitis C.
    Shimozuma Y; Ito T; Inokuchi M; Uchikoshi M; Miyashita M; Nozawa H; Shimazaki T; Hiroishi K; Imawari M
    J Med Virol; 2010 Dec; 82(12):2064-72. PubMed ID: 20981794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normal suppressive T cell function of Epstein-Barr virus-induced B cell activation in Graves' disease.
    Kahan A; Lefloch JP; Charreire J
    J Clin Endocrinol Metab; 1987 Sep; 65(3):555-60. PubMed ID: 3040797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral and cellular immunological factors as possible markers of clinical relapse in HLA-typed Graves' patients followed with time.
    Di Mario U; Vitillo M; Perfetti R; Mancuso M; Morellini M; Cappellacci S; Pozzilli P; Andreani D
    Horm Metab Res; 1989 May; 21(5):267-71. PubMed ID: 2789166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immortalized Epstein-Barr virus-positive B-cell lines obtained by prolonged culture of peripheral blood mononuclear cells from human immunodeficiency virus type 1-positive patients.
    Ruibal-Ares B; Belmonte L; Baré P; Scolnik M; Palacios MF; Bayo-Hanza C; Galmarini CM; Mendez G; de Bracco MM
    J Hum Virol; 2001; 4(4):200-13. PubMed ID: 11694848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization and clinical relevance of circulating CD4+CD28- T cells in Graves' disease.
    Wang F; Chen L; Shen Q; Liu T; Jiang L; Gu X; Chen L; Sun J; Liu C
    Immunol Lett; 2015 May; 165(1):47-51. PubMed ID: 25839128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyrotropin receptor autoantibodies induce human thyroid cell growth and c-fos activation.
    Huber GK; Safirstein R; Neufeld D; Davies TF
    J Clin Endocrinol Metab; 1991 May; 72(5):1142-7. PubMed ID: 1850754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production of thyrotropin receptor antibodies in acute phase of infectious mononucleosis due to Epstein-Barr virus primary infection: a case report of a child.
    Nagata K; Okuno K; Ochi M; Kumata K; Sano H; Yoneda N; Ueyama J; Matsushita M; Kuwamoto S; Kato M; Murakami I; Kanzaki S; Hayashi K
    Springerplus; 2015; 4():456. PubMed ID: 26322262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TSH-receptor autoantibodies: pathophysiology, assay methods, and clinical applications.
    Ehlers M; Allelein S; Schott M
    Minerva Endocrinol; 2018 Sep; 43(3):323-332. PubMed ID: 29265783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High frequency of B cells capable of producing anti-thyrotropin receptor antibodies in patients with Graves' disease.
    Fan JL; Desai RK; Dallas JS; Wagle NM; Seetharamaiah GS; Prabhakar BS
    Clin Immunol Immunopathol; 1994 Apr; 71(1):69-74. PubMed ID: 8137560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO).
    Giovanella L; Ceriani L; Garancini S
    Q J Nucl Med; 2001 Mar; 45(1):115-9. PubMed ID: 11456370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The negative correlation between thyrotropin receptor-stimulating antibodies and bone mineral density in postmenopausal patients with Graves' disease.
    Amashukeli M; Korinteli M; Zerekidze T; Jikurauli N; Shanava S; Tsagareli M; Giorgadze E
    J Investig Med; 2013 Jun; 61(5):842-7. PubMed ID: 23612147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease.
    Hirooka Y; Li C; Takagi J; Gotoh M; Habu S; Yasaka-Nomura T; Ishihara R; Nakasone Y; Nakamura R; Morikawa R; Otake K; Nogimori T; Ishizuki Y
    Int J Clin Pharmacol Res; 2004; 24(4):111-6. PubMed ID: 15754915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Close relationship between immunoglobulin secreting-cells and Epstein-Barr virus reservoir in patients infected with HIV.
    Ouedraogo DE; Tuaillon E; Rubbo PA; Bollore K; Foulongne V; Reynes J; Vendrell JP
    J Med Virol; 2014 Jan; 86(1):30-7. PubMed ID: 24114930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.
    Schott M; Eckstein A; Willenberg HS; Nguyen TB; Morgenthaler NG; Scherbaum WA
    Horm Metab Res; 2007 Jan; 39(1):56-61. PubMed ID: 17226115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of TSH receptor antibodies in the management of Graves' disease.
    Matthews DC; Syed AA
    Eur J Intern Med; 2011 Jun; 22(3):213-6. PubMed ID: 21570635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-TNFα therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation.
    Lapsia S; Koganti S; Spadaro S; Rajapakse R; Chawla A; Bhaduri-McIntosh S
    J Med Virol; 2016 Feb; 88(2):312-8. PubMed ID: 26307954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.